Replies to post #186581 on Biotech Values

[DewDiligence]

ENTA—The contractual confidentiality of V-Pak Scripts written by ESRX’s clients may be causing some investors to underestimate ABBV’s market share at this early stage of the V-Pak launch:

https://t.co/Z0Us9pPMyd
https://t.co/wopHVjZpPT